Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Q1 2025 Management View CEO Steve Westhoven highlighted a strong start to fiscal 2025, with strategic initiatives driving growth across all business segments. New Jersey Natural Gas achieved a ...

Today's Research Daily features the Q4 earnings season scorecard and updated analyst reports on 16 major stocks, including Meta Platforms (META), Mastercard (MA) and Adobe (ADBE), as well as two micro ...

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

Palantir's U.S. commercial revenue surged 64% YoY, driven by AIP technology, but faces intensifying competition and high ...

Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings.

France's BNP Paribas reported a forecast-beating jump in net income in the fourth quarter as its investment bankers rode a surge in trading activity, but the lender lowered a key profit target for ...

Excluding South Erregulla, we credit group production increasing to 35 petajoules or 6.0 million barrels of oil equivalent by fiscal 2028, from 1 mmboe in fiscal 2024. On the heels of Walyering, this ...

Operating income was $6.2 million in the first quarter of fiscal 2025, compared to $9.7 million in the prior year period. This led to net earnings in Q1 ’25 of $5.1 million, compared to $7.3 million ...